Therapeutic Advances in Endocrinology and Metabolism (Jun 2012)

Antihypertensive treatment in patients with class 3 obesity

  • Jens Jordan,
  • Sam W. Boye,
  • Stephanie Le Breton,
  • Deborah L. Keefe,
  • Stefan Engeli,
  • Margaret Forney Prescott

DOI
https://doi.org/10.1177/2042018812445573
Journal volume & issue
Vol. 3

Abstract

Read online

Background : Even though patients with class 3 obesity (body mass index ≥ 40 kg/m 2 ) are prone to arterial hypertension and respond less to antihypertensive drugs, they are not considered in hypertension treatment guidelines and data from prospective clinical trials are lacking. Methods : In a post hoc analysis of a clinical trial, we compared patients with class 3 obesity with patients with class 1/2 obesity. Results and Conclusions : Blood pressure control in class 3 obesity was less likely to be achieved with hydrochlorothiazide monotherapy. While addition of amlodipine, irbesartan, or aliskiren to hydrochlorothiazide improved the blood pressure response, amlodipine was less effective and induced peripheral edema in 19% of patients with class 3 obesity.